Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
1/9/25 Sanofi (SNY) Sarclisa for Multiple Myeloma (MM) Subscribers Only Subscribers Only Subscribers Only
1/8/25 LB Pharmaceuticals LB-102 for Schizophrenia Subscribers Only Subscribers Only Subscribers Only
1/7/25 Metsera MET-097i for Obesity Subscribers Only Subscribers Only Subscribers Only
1/6/25 PharmaEssentia (6446) Besremi for Essential Thrombocythemia (ET) Subscribers Only Subscribers Only Subscribers Only
1/2/25 Neumora Therapeutics (NMRA) Navacaprant for Major Depressive Disorder (MDD) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
09/12/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/16/2024 Subscribers Only Subscribers Only Company - Analyst/R&D Update
10/30/2024 Subscribers Only Subscribers Only Progress Update - Development Review
11/15/2024 Subscribers Only Subscribers Only Partnership - Acquisition Completion
11/19/2024 Subscribers Only Subscribers Only Partnership - Acquisition Completion